|
``No general counsel or CEO wants to have to explain to his board why the company's name is appearing on the front page of a news article in a scandal..."
Bloomberg News reports that corporations that had until now been shielded by Republicans who controlled Congress--as for example, the pharmaceutical industry which is reported to have given 68% of its 2006 campaign gifts to Republicans; and Haliburton, which gave 92% of its contributions to Republicans--are now scrambling to hire public relations professionals. The 2006 elections are proving to be a boon for lobbyists, PR firms and lawyers--especially those with relationships to Democrats--are being anxiously sought to buy favor with Democrats. "In the era of instant news, even the threat of a congressional investigation can impact a company's brand, reputation, and, just as importantly, its bottom line...'' Paul Fitzhenry, a spokesman for New York-based Pfizer, and Glover Park partner Joel Johnson, a former Clinton administration and Senate Democratic staff member, said the group has handled a number of assignments for the drugmaker for about two years. Lobbyists with Washington experience are considered particularly valuable when chief executive officers face nationally televised hearings. Cong. Henry Waxman will be presiding over hearings about Haliburton, the company which was headed by Vice President Dick Cheney. Waxman presided over one of the most famous on April 14, 1994, when seven tobacco- industry CEOs testified that they didn't add nicotine to their cigarettes. Public hearings entail much greater risk with respect to a company's reputation than does civil litigation which is mostly resolved away from the public glare with incriminating documents often sealed from public view. Lilly's battle to keep a court injunction preventing the Zyprexa documents from being publicly circulated is a prima facie example. Indeed, Bloomberg reports that the pharmaceutical industry may be the biggest target for investigators. The House voted Jan. 12 to require the Medicare program to negotiate prices with drug companies; five congressional committees plan hearings into industry practices, including the generic-drug approval process and drug safety. Can it be that we will see a dozen (or so) pharmaceutical industry CEOs testify under oath about their marketing drugs whose lethal effects they knew but concealed? Contact: Vera Hassner Sharav 212-595-8974
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
http://www.bloomberg.com/apps/news?pid=20601070&sid=a8fyOQYvbFQ8&refer=politics Pfizer, Halliburton Grab Democrats as Hearings Loom By Jonathan D. Salant January 31, 2007 Jan. 31 (Bloomberg) -- Pharmaceutical companies and Iraq war contractors, both heavy Republican contributors, are among the companies scrambling to hire lobbyists with Democratic ties as they prepare for congressional investigative hearings next week. Pfizer Inc., the world's biggest drugmaker, has hired the Glover Park Group, whose partners include Joe Lockhart, a former spokesman for President Bill Clinton, and Howard Wolfson, a spokesman for Senator Hillary Clinton's presidential campaign. Roche Holding AG picked as its lobbyist William Clyburn, cousin of the House's third-ranking Democrat, Jim Clyburn of South Carolina. The increased hiring coincides with the Democratic congressional sweep that has sent shudders through corporate boardrooms. ``No general counsel or CEO wants to have to explain to his board why the company's name is appearing on the front page of a news article in a scandal,'' said Nick Allard, a partner in the law and lobbying firm of Patton Boggs LLP, which just landed military contractor Halliburton Co. as a client. ``Firms and industry groups that have not yet been represented are talking to firms all over town.'' Representative Henry Waxman, 67, the California Democrat who heads the House Oversight and Government Reform committee, plans to hold hearings beginning Feb. 6 on Iraq contractors. The committee has asked executives from Halliburton to testify. The Cheney Connection Halliburton, a Houston-based oilfield services company once headed by Vice President Dick Cheney, gave 92 percent of its political-action committee contributions to Republicans for the 2006 campaign, according to the Center for Responsive Politics, a Washington research group. The company's new firm, Patton Boggs, counts Democratic lobbyist Thomas Boggs among its name partners. KBR Inc., a Halliburton unit, hired the law and lobbying firm Akin Gump Strauss Hauer & Feld LLP, whose partners include Democratic former House Speaker Thomas Foley. ``Halliburton retains firms with deep experience in the industry, on Capitol Hill and in the administration to help us navigate the policy arena,'' Melissa Norcross, a spokeswoman for Halliburton and KBR, said in an e-mailed comment. Lobbyists with Washington experience are considered particularly valuable when chief executive officers face nationally televised hearings. Waxman presided over one of the most famous on April 14, 1994, when seven tobacco- industry CEOs testified that they didn't add nicotine to their cigarettes. Raising the Stakes Public hearings raise the stakes for corporations, said Mark Paoletta, a lawyer who helped run investigations for the House Energy and Commerce Committee when Republicans were in control. ``The company has a much larger risk with respect to its reputation'' than in civil litigation that can be resolved away from the public glare, he said. Some Republican lobbyists are also benefiting from the increased congressional attention. Paoletta and another Energy and Commerce lawyer, Andrew Snowdon, just joined the Washington office of lobbying and law firm Dickstein Shapiro LLP. Mark Corallo and Barbara Comstock, two former Justice Department officials who have formed their own lobbying firm in Alexandria, Virginia, are talking to representatives of oil and drug companies. One of the pair's new clients, security firm Blackwater USA of Moyock, North Carolina, is scheduled to testify next week before Waxman's committee, Corallo said. The panel is probing possible waste and fraud in Iraq war contracts. `Congressional Crosshairs' ``When we realized that the political winds were blowing the other way, we understood there would be a market,'' said Corallo. Companies that ``escaped oversight'' for more than a decade ``are going to find themselves in the congressional crosshairs,'' he said. The pharmaceutical industry, which the Center for Responsive Politics says gave 68 percent of its 2006 campaign gifts to Republicans, may be the biggest target for investigators. The House voted Jan. 12 to require the Medicare program, which provides health care for the elderly and disabled, to negotiate prices with drug companies; five congressional committees plan hearings into industry practices, including the generic-drug approval process and drug safety. Paul Fitzhenry, a spokesman for New York-based Pfizer, and Glover Park partner Joel Johnson, a former Clinton administration and Senate Democratic staff member, said the group has handled a number of assignments for the drugmaker for about two years. First Registration This year marks the first time Glover Park has registered as the company's lobbyists, congressional filings show. Johnson said the firm registered `` when it became evident that the inside role was to require outside contacts'' on legislative matters. Lockhart and Wolfson, the Glover Park partners, aren't listed on congressional forms as the firm's lobbyists for Pfizer. William Clyburn didn't return phone calls seeking comment. Roche, based in Basel, Switzerland, had no immediate comment when asked about the investigations. Thousand Oaks, California-based Amgen Inc., the world's largest biotechnology company, hired two firms in the last two months, congressional filings show. ``It certainly is a different political landscape,'' Amgen spokeswoman Kelley Davenport said. Amgen's new lobbyists include the Duberstein Group, led by Kenneth Duberstein, former chief of staff to President Ronald Reagan, and Michael Berman, a veteran Democratic political operative. The company also hired Lent, Scrivner & Roth LLC, whose partners include former Republican Representative Norman Lent of New York and Alan Roth, staff director of the House Energy and Commerce Committee when it was previously under Democratic control. Republican Lobbyist Another Washington law firm, Venable LLP, brought in Raymond Shepherd III, a Republican who is former chief counsel to the Senate Homeland Security and Governmental Affairs investigations subcommittee, to run its new congressional-investigation group. Birch Bayh, a former Democratic senator from Indiana, is a partner at the firm. Venable's new clients include London-based drugmaker AstraZeneca PLC, maker of Crestor, the fastest-growing cholesterol medicine. ``In the era of instant news, even the threat of a congressional investigation can impact a company's brand, reputation, and, just as importantly, its bottom line,'' said Gloria Dittus, head of Dittus Communications, a Washington-based public-affairs firm. ---------- To contact the reporter on this story: Jonathan D. Salant in Washington at
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
. FAIR USE NOTICE: This may contain copyrighted (C ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.
|